An Important Advance in Brain Tumor Diagnosis: The CSF-BAM Cerebrospinal Fluid Test
In this article
⚗️ New Hope in Brain Tumor Diagnosis: The CSF‑BAM Test
Surgical biopsy has been the most commonly used method for diagnosing suspicious brain lesions. However, biopsy is both invasive and risky , particularly for deep lesions or those near vital structures, where major complications are possible. Cytology and imaging are also often insufficient for diagnosis. Developed in this context, CSF-BAM provides high accuracy through multibiomarker analysis of a small cerebrospinal fluid (CSF) sample.
📊 Study Design
Researchers used two separate cohorts. In the first, 206 CSF samples were assessed from patients with glioma, medulloblastoma, brain metastases, and CNS lymphoma. Subsequently, 129 additional CSF samples were used to test the most common aggressive brain tumors, evaluating performance separately across tumor groups.
The analytical approach combined BCR/TCR sequencing, aneuploidies and tumor-specific mutations in one panel, analyzed through DNA duplex amplification.
📖 Publication:
Research Brief · August 25, 2025
Detection of human brain cancers using genomic and immune cell characterization of cerebrospinal fluid through CSF-BAM
Authors include Alexander H. Pearlman, Yuxuan Wang, Anita Kalluri, Joshua D. Cohen, Bert Vogelstein, Christopher Douville, Chetan Bettegowda, and others
🔗 Cancer Discovery · DOI: 10.1158/2159-8290.CD-24-1788
🚀 Key Findings
The study did not report PPV/NPV figures; these metrics vary with clinical prevalence . Only sensitivity and specificity are shown here.
Decision Tree
🧬 Analytes and Test Rationale
- BCR/TCR sequences: Reflect the adaptive immune repertoire in CSF; clonal expansions may indicate cancer-related immune responses.
- Aneuploidies: Copy number changes—gains/losses—capture large-scale genomic imbalance.
- Tumor-specific mutations: Driver or characteristic alterations support tumor origin.
- Combined interpretation: Compared with a single marker, reduces false positives and diagnostic uncertainty.
🏥 Potential Clinical Scenarios
- Lesions with high biopsy risk or difficult anatomical access.
- Cases where imaging/cytology is inconclusive .
- During follow-up, suspected recurrence or noninvasive monitoring of treatment response.
- Differential diagnosis through combined tumor signals and immune profiling.
⚠️ Limitations and Cautions
- Selected cohorts → generalizability requires larger, multicenter validation.
- A negative result does not definitively rule out disease; further investigation is needed when clinical suspicion is high.
- Preanalytical factors—sampling, storage, contamination—may affect performance.
👨⚕️ Commentary
CSF-BAM identifies not only tumors but also immune-cell populations in CSF, adding information in difficult cases. For example, when biopsy is impossible or cytology and imaging are insufficient, immunological signatures may be decisive for diagnosis.
In our view, the test's greatest strength is specificity. At 100% specificity, false-positive risk is virtually absent, potentially allowing physicians much greater confidence in biopsy decisions after a positive result.
📝 Conclusion
- CSF-BAM, 81% sensitivity and 100% specificity are notable.
- Multibiomarker analysis offers diagnostic accuracy and additional clues about the immune environment .
- With larger future validation studies, this test is a strong candidate for reducing biopsy needs in brain tumors.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.